| US 11,814,371 B2 | ||
| Heterocyclic compound | ||
| Guanglong Sun, Shanghai (CN); Chunli Shen, Shanghai (CN); Chengde Wu, Shanghai (CN); and Shuhui Chen, Shanghai (CN) | ||
| Assigned to MEDSHINE DISCOVERY INC., Jiangsu (CN) | ||
| Appl. No. 17/905,538 | ||
| Filed by MEDSHINE DISCOVERY INC., Nanjing (CN) | ||
|
PCT Filed Mar. 4, 2021, PCT No. PCT/CN2021/079093 § 371(c)(1), (2) Date Sep. 2, 2022, PCT Pub. No. WO2021/175290, PCT Pub. Date Sep. 10, 2021. |
||
| Claims priority of application No. 202010144412.8 (CN), filed on Mar. 4, 2020. | ||
| Prior Publication US 2023/0167098 A1, Jun. 1, 2023 | ||
| Int. Cl. C07D 405/14 (2006.01); C07D 401/14 (2006.01) | ||
| CPC C07D 405/14 (2013.01) [C07D 401/14 (2013.01)] | 10 Claims |
|
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof,
 wherein, R1 is H, F, Cl, Br, I, OH or NH2; R2 is H, F, Cl, Br, I, OH or NH2; R3 is H, F, Cl, Br, I, OH, C1-3 alkyl or C1-3 alkoxy, wherein the C1-3 alkyl and C1-3 alkoxy are each independently and optionally substituted by 1, 2 or 3 Ra; R4 is H or C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted by 1, 2 or 3 Rb; T1 is N or CR5; T2 is N or CR6; T3 is N or CR7; E1 is O or NR8; R5, R6 and R7 are each independently H, F, Cl, Br, I, OH or NH2; R8 is H, C1-3 alkyl, C1-3 alkoxy, —C(═O)C1-3 alkyl or —S(═O)2C1-3 alkyl, wherein the C1-3 alkyl, C1-3 alkoxy, —C(═O)C1-3 alkyl and —S(═O)2C1-3 alkyl are each independently and optionally substituted by 1, 2 or 3 Rc; Ra, Rb and Rc are each independently F, Cl, Br, I, OH or NH2. |